← All trials
NCT06551181
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2024
- Primary completion
- Mar 28, 2025
- Completion date
- Sep 12, 2025
- First posted
- Aug 13, 2024
- Last posted
- Aug 13, 2024
- Enrollment
- 2600
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.